Transdermal Estradiol for Women with Premature Ovarian Insufficiency and Migraine with Aura

Indications and Guideline Recommendations

The European Society of Human Reproduction and Embryology (ESHRE) recommends transdermal 17β‑estradiol as the preferred hormone replacement therapy for women with premature ovarian insufficiency (POI) who experience migraine with aura. 1
ESHRE explicitly advises transdermal estradiol for hypertensive women with POI, and the same recommendation is extended to women with migraine with aura because of its lower thrombotic risk compared with oral formulations. 1
According to ESHRE, if migraine symptoms worsen during hormone replacement therapy, clinicians should consider changing the route of administration, favoring transdermal delivery as a safer option. 1
The guideline specifies that 17β‑estradiol is the estrogen of choice for replacement therapy, preferred over ethinylestradiol or conjugated equine estrogens, and that transdermal delivery avoids first‑pass hepatic metabolism. 1

Transdermal estradiol is associated with a lower risk of thrombotic events compared with oral estrogen preparations, as demonstrated in recent reviews. 2, 3
Migraine with aura is a contraindication for combined oral contraceptives containing ethinylestradiol, but this restriction does not apply to physiologic hormone replacement with transdermal 17β‑estradiol in POI; HRT doses are replacement‑level, not supraphysiologic. 5, 2

For a 40‑year‑old woman with POI, initiate transdermal patches delivering 50–100 µg of 17β‑estradiol per 24 hours. 4
Because the patient has an intact uterus, add a progestogen regimen such as medroxyprogesterone acetate 10 mg daily for 12–14 days each month or micronized progesterone 200 mg daily for 12–14 days each month. 1, 4
Continue hormone replacement therapy at least until the average age of natural menopause (approximately age 51). 1

Women with POI retain a residual capacity for spontaneous ovulation (≈ 5–10 % conception rate); therefore, if contraception is desired, additional contraceptive methods should be discussed. 5, 2

Perform annual monitoring that includes blood pressure, body weight, smoking status, and assessment of symptom control, with particular attention to any changes in migraine frequency or severity. 1